Psychedelic Support

Self-study course available! 👉 The Endocannabinoid System: Exploring Synergy and Homeostasis. This immersive online course peers deep into the body's most densely populated receptor system, the Endocannabinoid System (ECS). In this course, you will discover the profound implications of the ECS, an intricate biological network that plays a crucial role in maintaining physiological homeostasis across numerous organ systems within the body. We will investigate the evolution of the ECS and its significant impacts on human health and well-being. Our exploration will also encompass the intricacies of cannabis and cannabinoids, offering an understanding of their interaction with ECS receptors. We will discuss the entourage effect - a concept of botanical synergy where the combined effect of a plant's components is greater than the individual parts. While our journey begins with the ECS and cannabis, it extends beyond, reaching into other botanicals and holistic therapies. This course will provide a basic understanding of the ECS, botanical synergies, and their applications in holistic health. This knowledge will empower you to apply these concepts across a wide range of therapeutic practices, fostering a more integrative approach to health and wellness. Learn more and purchase immediate access here 🔗 https://lnkd.in/gQfa7rAW

Newsweek: "Roughly one in 10 American adults suffer from a depressive illness each year, according to Johns Hopkins Medicine, while one in four suffer from a diagnosable mental health disorder. Previous research has suggested that psilocybin—the active ingredient in magic mushrooms—may offer effective relief against major depressive disorder symptoms, with a short, two-dose treatment course lasting for up to a year. While psychotherapy has shown promise for treating a range of mental health disorders and addictions, psilocybin-assisted therapy has not yet been given the greenlight by the FDA. That doesn't mean they aren't considering it. Several breakthrough therapy designations have been granted for psilocybin in the treatment of resistant depression—that is, depression that does not respond to at least two different types of antidepressants—and a broader approval may be on the horizon. But as this milestone decision approaches, how many people actually stand to benefit from this kind of treatment? In a new study from Emory University, the University of Wisconsin-Madison, and UC Berkeley, researchers set out to investigate the potential demand for psilocybin-assisted therapy for depression in the United States. By combining data on depression prevalence—based on national surveys—with eligibility criteria for recent landmark clinical psychotherapy trials, the team determined that between 56 and 62 percent of those currently receiving treatment for depression—that is, 5.1 to 5.6 million Americans—could qualify for psilocybin therapy if it is approved. "

You’re fretting over the details of your presentation. You’ve lost a couple of nights of sleep. You’re worried that the committee won’t approve your funding request. On game day, you’re nervous, and your heart is racing. Do you have an anxiety disorder, or are these just normal jitters? Here is a thorough guide for you to recognize typical worrying and signs of an anxiety disorder 👉 https://lnkd.in/gqmjhSyS

So, you’ve heard the buzz about psychedelics, and perhaps you’re curious to try them yourself. Maybe you’ve caught wind of the research on psilocybin for depression or anxiety, or you’ve read news reports about localities across the country decriminalizing plant medicines. Perhaps you’ve been intrigued by word on the street about friends going to ayahuasca ceremonies or retreats in the jungle. Or, you could simply be curious to expand your consciousness and traverse the realms beyond mundane reality. Whatever brought you here—whether you’re looking to heal, have fun, garner a spiritual connection, or just explore what psychedelics have to offer—welcome to the threshold of a potentially life-changing journey. But where do you start? The world of psychedelics can seem vast and intimidating, what with the different compounds out there, how to take them, how to prepare, and how to ensure that you have a safe—and hopefully beneficial—experience. This guide can help you on your psychedelic path 👉 https://lnkd.in/gQYMAnXH

⭐ Workshop October 24th ⭐ For clinicians and guides interested in the application of psychedelic-assisted therapy with individuals struggling with an eating disorder or disordered eating. The trainers will draw on their theoretical knowledge and practical experience from research, clinical, and non-clinical settings using a range of substances including psilocybin, ayahuasca, ketamine, and MDMA. Special considerations for medicine work in this context will be reviewed, from screening, preparation, and dosing to integration and beyond. This training will also include a module on the role of supporting others (family members or close friends) in the process, in line with advances in the field of eating disorder treatments. What to expect: 👉 What is an eating disorder? Beyond the DSM: Lessons learned from psychedelic journeys Common themes that arise during ED journeys and ways to support healing and growth, including ways to respond to resistance and despair 👉 Skills development in the attending to and processing of emotions drawing on emotion transformation theory 👉 Skills development to support a kinder, more compassionate relationship with the body 👉 Strategies for the management of eating disorder thoughts and behaviors pre, during, and after the psychedelic experience. 👉 Concrete strategies to support the broadening of the individual’s care network to optimize outcomes. This includes the use of emotion coaching skills from EFFT. Continuing Education (CE) credits are provided through the Canadian Psychological Association. Register now at: https://lnkd.in/geE3BMU5

According to the World Health Organization (WHO), approximately 703,000 people die by suicide each year worldwide. Suicide is a serious global public health issue occurring in every region of the world. It is a devastating event that impacts families, communities, and entire nations, leaving lasting effects on those who are left behind. Suicide can occur at any stage of life; in 2019, it was the fourth leading cause of death among 15- to 29-year-olds worldwide. In the United States, suicide is a leading cause of death. In 2022, there were approximately 49,476 recorded deaths by suicide, which is about one death every 11 minutes. Suicide was among the top 9 leading causes of death for people ages 10 to 64 in 2022 and was the second leading cause of death for people ages 10 to 14 and 25 to 34. Suicide is a critical public health concern that we can prevent with timely, evidence-based, and often low-cost interventions. In support of #BeThe1To campaign, we've published the 5 Actions Steps to Help Save a Life. We invite you to read in full 👉 https://lnkd.in/eJSKNSmN

MDMA-assisted group therapy, developed in the 1970s, has evolved with unique characteristics compared to other psychedelic group models. Join Psychedelic Support and Chris Stauffer, MD, on September 21st from 12-1 PM PT (Pacific Time) for an insightful discussion on the evolution of MDMA-Assisted Group Therapy for PTSD. Dr. Stauffer will compare early practices with current protocols, explore how MDMA influences group dynamics, and discuss how this model could expand access to therapy once approved. Register free 👉 https://lnkd.in/gGHcjhzZ

There is so much to learn about p$ychedel!cs as a treatment for Perinatal/Postpartum Mood and Anxiety Disorders (PMADs). Kate Kincaid, LPC shares so much with us. Read what we covered on this important topic together here 👉 https://lnkd.in/gsn-3pEk

After decades of research and clinical trials, the US Food and Drug Administration (FDA) recently denied an application to approve the psychedelic drug MDMA, combined with talk therapy, as a treatment for Post Traumatic Stress Disorder (PTSD). The FDA rejection has called for further research. But despite the rejection, MDMA-Assisted Therapy, remains one of the most powerful and promising tools for healing trauma and relationships. Why, Then, Has the FDA Rejection of This Potentially Formidable Treatment Occurred? Read on to hear thoughts from Darek Dawda, PhD, CPsych, an experienced psychotherapist trained in MDMA-Assisted Therapy 👉 https://lnkd.in/gBxHpi78